VOR Vor Bio, Inc.

NASDAQ
$19.56

Vor Bio, Inc. (VOR) is expected to report earnings on January 29, 2027, before the market open. The consensus earnings estimate is a loss of $0.92 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.1% since its last earnings release on October 30, 2026.

Vor Bio Missed Consensus Estimates
Friday, October 30, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 29
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($0.92)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $19.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vor Bio, Inc.

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.